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Hemophilia is an x-linked condition which results in a deficiency of coagulation factors, 
either factor VIII (in hemophilia A) or factor IX (in hemophilia B)
1
. In moderate and severe 
cases, the factor deficiency leads to recurrent spontaneous hemarthroses, which in turn lead to 
contractures and early degenerative joint disease. The knee is the commonest joint to be affected 
by hemophiliac arthropathy, and there is now a large body of evidence to guide surgeons in the 
management of such patients. The aim of this article is to assess the current evidence for surgical 
interventions in patients with hemophilia, with a special focus on the knee. 
 
General concepts in hemophilia and its treatment 
Hemophilia is one of the commonest bleeding disorders encountered in orthopedic 
surgery. It is an X-linked recessive condition affecting one in 5000 men. Hemophilia is a 
disorder of the initiation of coagulation, and is due to reductions in the concentrations of, or the 
presence of a less active version of, one of two coagulation factors, factor VIII and factor XI. 
The deficiency of these factors results from a defect in one of two genes on the X chromosome, 
F8 (which codes for factor VIII) and F9 (which codes for factor XI). Hemophilia A, the 
commonest form, is a deficiency of factor VIII, and hemophilia B (previously known as 
Christmas disease) is a deficiency of factor XI
1
. Given the X-linked mode of inheritance, most 
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females with a single copy of the faulty gene are carriers, and most are asymptomatic although a 




The severity of hemophilia is graded according to the amount of the deficient coagulation 
factor present in the circulation. This is expressed as a percentage (with normal being 100%): 
mild disease results from a concentration of between 5-40% of normal; moderate disease from 1-
5% and those with severe disease have a concentration of less than 1%
2
. Those with severe 
disease bleed spontaneously, whilst in mild and moderate disease, excessive bleeding is observed 
after minor trauma, surgery or dental work. 
In developed countries (20-30% of the world population), the orthopedic problems of 
hemophilia have reduced since the introduction of prophylaxis using concentrates of the deficient 
coagulation factor
3
. The use of prophylaxis has the effect of turning serious hemophilia into a 
milder form by maintaining the factor level above 1% permanently; doses are titrated to the 
concentration of factors and the incidence of bleeds
4
. This in turn has led to a reduction in the 
number of orthopedic procedures performed for hemophilia – Tobasse et al report a dramatic 
decline in orthopedic interventions in the first decade of this century in a study of patients 
enrolled in the US Universal Data Collection program; whilst 7.2% of patients underwent an 
orthopedic intervention in 2000, this fell to just 1.7% in 2010
3
. However, the huge economic cost 
of primary prophylaxis means that 70-80% of the world’s hemophiliac population does not have 
access to such treatment; indeed, some regions of the world do not even have access to treatment 
with factor concentrate when bleeding occurs. Even in developed countries, while children with 
hemophilia have an excellent prognosis from the point of view of their musculoskeletal health, 
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there remain a cohort of older adults who continue to face the musculoskeletal consequences of 
the hemarthroses that they suffered before the advent of modern therapies. 
The major complication of treatment with coagulation factor concentrates is the 
generation of inhibitors. These are antibodies which are raised against the coagulation factor 
concentrate, decreasing the efficacy of treatment and necessitating the use of higher doses of 
factor concentrate
5
. Whilst inhibitors are rare in hemophilia B (affecting approximately 3% of 
patients), they are found in 13% of patients with hemophilia A and up to a third of patients when 
the disease is severe
6
. A proportion of these patients can be treated with immune tolerance 
induction (ITI) which involves exposing the patient to prolonged high concentrations of 
coagulation factors in order to induce peripheral tolerance
5
.  
While improvements in medical prophylaxis and treatment for hemophilia have improved 
outcomes and reduced the need for orthopedic interventions in developed countries
3
, 
musculoskeletal problems remain common in hemophiliacs. Such is the complexity of managing 
such patients that they are best approached in the context of a multidisciplinary team, with 
members from hematology, orthopedic surgery, physical medicine and rehabilitation, pediatrics, 
psychology, physiotherapy and nursing. The correct periprocedure management of these patients 
is perhaps as important as the procedure itself.  
The musculoskeletal disease in hemophilia is a result of an inflammatory response to the 
presence of hemoglobin-derived iron in the knee joint. The inflammation leads to a severe, 
destructive arthropathy with cartilage destruction and bony erosions (Fig. 1). A major feature of 
the disease is stiffness; over time, severe arthrofibrosis forms leading to progressive contractures 
of the joint
7
 (Fig 2). The principle of treatment of hemophiliac arthropathy is to prevent 
hemarthroses (which is largely performed through medical means), to treat the hemarthroses (in 
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order to prevent the inflammatory response), to treat the synovitis which results from this 
inflammation, and finally, in cases of severe joint destruction, to effectively reconstruct the joint 
to facilitate the relief of pain and the restoration of function.  
 
Pediatric orthopedic management of the knee in hemophilia 
Treatment of acute hemarthroses 
Symptom control in hemophiliac arthropathy is best prevented by the prevention and 
prompt treatment of hemarthroses and the synovitis that results. In the acute setting, 
hemarthroses should be treated with a single dose of factor concentrate; the European 
Hemophilia Therapy Standardization Board have recommended a dose of 25-40IU/kg of factor 
VIII in patients with hemophila A without inhibitors, with an increased dose in patients with 
post-traumatic bleeds
8
. Analgesia and non-steroidal anti-inflammatory drugs are helpful but there 
is no evidence base to recommend the use of corticosteroids in the acute setting. The European 
Hemophilia Therapy Standardization Board (EHTSB) has prepared guidelines on the 
management of acute bleeds in hemophilia and recommends against the use of corticosteroids 
either orally or by intra-articular injection
8
. The use of ice may provide symptomatic relief but is 
controversial as it may impair coagulation, prolonging the bleeding episode
9
. The orthopedic 
surgeon is most likely to be called upon to perform arthrocentesis, which merits inclusion in this 
article as a simple but very effective procedure, which can be performed in an out-patient setting. 
It allows the effective drainage of a painful tension hemarthrosis, and may have a prognostic 
benefit in preventing the inflammatory response associated with the hemarthrosis
10
. There are no 
studies available to support the use of arthroscopy in the setting of an acute hemarthrosis and 
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again is not recommended in the EHTSB guideline
8
. Physiotherapy is useful for rehabilitation 
after the acute bleed. 
 
Synovectomy 
After recurrent hemarthrosis, the hemophiliac patient’s knee reaches a state of chronic 
synovitis (synovial hypertrophy), which in turn perpetuates the tendency towards new bleeding. 
Under these circumstances, this hypertrophic synovium must be resected using non-surgical 
(radiosynovectomy and chemical synovectomy) or surgical procedures (arthroscopic or open 
synovectomy). The aim of all of these methods is to reduce the frequency and intensity of the 
hemarthrosis in patients in whom solely medical management has failed. Synovectomy has the 
effect of improving knee function, reducing the frequency of hemarthroses, reducing the 
incidence of flexion contractures and therefore improving quality of life. Whichever means is 
used to perform synovectomy, it should be accompanied by physiotherapy and continuous 
passive motion may be used to maintain range of movement following intervention. 
In radiosynovectomy, a beta-emitting colloidal radionucleotide is introduced into the 
joint by injection. Whilst a number of agents are used, usually yttrium-90 is used for the knee 
and rhenium-186 is used for the ankle and the elbow as the synovium is thicker in the knee and 
yttrium-90 has a greater therapeutic penetration power than rhenium-186 (although no clinical 
difference has been demonstrated between the two agents in practice)
11
. In the USA and other 
countries phosphorus-32 (P-32) is used. The radionucleotides are taken up by cells within the 
synovium, and the exposure to the radiation results in reduction in the rate of proliferation of 
these inflammatory cells, and leads to necrosis and subsequent fibrosis of the synovium itself
12
. 
In chemical synovectomy an oxidant such as osmic acid or rifampicin is introduced into the joint 
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by multiple weekly injections
13
. In arthroscopic or open synovectomy, the synovium is excised 
directly. Given the tendency of synovium to bleed, surgical synovectomy necessitates good 
perioperative hemostasis, and the control of coagulation factors intra-operatively using infusions 
of the deficient factor (either continuous or bolus).  
There is now good evidence that synovectomy is an effective procedure for the 
prevention of recurrent hemarthroses in hemophilia although there is little evidence that it 
prevents the development of secondary arthritis
14
. This latter point is surprising: whilst it might 
be expected to slow the development of degenerative change by limiting the exposure of the joint 
to the high levels of hemosiderin which are thought to be the cause of degenerative change in 
hemophilia, all series show the development of degenerative change in spite of synovectomy. 
The progression of degenerative change may be slowed: none of these studies are comparative 
and, whilst degenerative change is reported in all, it is not clear what degree of degeneration 
would be expected had synovectomy not been performed. In addition to removing the need for 
treatment of symptomatic hemarthroses, synovectomy improves knee pain and function and 
slows the reduction in range of movement and the development of flexion contractures
13,15
. The 




There are extensive published results to support the use of radiosynovectomy and it is in 
widespread use across Europe. The largest such study is a retrospective review of 500 cases with 
a mean follow-up of 18.5 years (0.5-38)
17
. Both yttrium-90 (
90
Y, in 64% of cases) and rhenium-
186 (
186
Re, in the remaining 36%) were used. The series involves 192 knees as well as ankles 
and elbows, and the results are presented for the group overall rather than being classified by 
joint; however, the size and length of follow-up merits this study’s inclusion here. Overall, there 
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was a marked and statistically significant decrease in the incidence of hemarthrosis, from a 
median of 6 per six months (range 2 to 8) to a median of 1.9 (range 0-2, p<0.001), together with 
statistically significant reductions in pain and clinical synovitis scores (both p<0.001). There was 
no indication that radiographic progression was slowed. One fifth of patients required two 
injections and approximately one tenth required three; only 6.3% required surgery, either 
arthroscopic synovectomy or TKA.  
The largest series examining the results of radiosynovectomy for knees alone is that of 
Turkmen et al
18
 who examined 82 patients undergoing radiosynovectomy with 
90
Y. As with the 
Rodriguez-Merchan study, all cases were performed under a continuous infusion of coagulation 
factors. Again, there was a substantial reduction in bleeds, from 12.7 per six months to 0.6 
following treatment, although no statistical analysis was presented with these figures. No 
radiographic outcomes are given. Many smaller studies exist which report similar results for 
radiosynovectomy (Table 1).  
Radiosynovectomy has been in use for forty years and few major complications have 
been reported
19
. However, in particular given the pediatric population who are most likely to 
receive radiosynovectomy, there have been concerns regarding the dose of ionizing radiation 
which patients are being exposed to
19
. There has been a single report of two cases of acute 
lymphocytic leukemia in children who with hemophilia who had received P-32 
radiosynovectomy, but causation is not clear
20
. More recently, Infante-Rivard et al have 
demonstrated no evidence of a dose-response relationship between exposure to 
radiosynovectomy and risk of malignancy
21
. Whilst some authors have reported the presence of 
reversible chromosomal aberrations following radiosynovectomy, others have found no evidence 
of an effect
19
. In fact, the dose of radiation involved in radiosynovectomy is low at 
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approximately 0.74 millisieverts (mSv); normal environmental exposure is approximately 2mSv 
per year. A recent systematic review has suggested no evidence of an increase in malignancies 
related to radiosynovectomy
19
. Other complications of radiosynovectomy are rare; a recent case 
report has documented two cases of cutaneous ulceration after radiosynovectomy but this is the 
first time this has been reported
22
. There is no clinical evidence that radiosynovectomy has any 
negative effects on articular cartilage; an animal study has demonstrated only transient 




There are fewer studies on chemical synovectomy. One study (Table 1) reports the 
outcomes of 22 knees using rifampicin, whilst another study reports the outcomes of 72 knees 
treated with osmic acid although knees are not reported separately rendering detailed analysis 
impossible
24,25
. Chemical synovectomy has been described in cases where radiosynovectomy is 
not available or contraindicated (for instance, in countries where the use of these agents is 
disallowed in children)
13
. Agents used include osmic acid and rifampicin; in all published reports 
it is noted that a painful inflammatory response takes place following chemical synovectomy and 
a period of immobilization with analgesia is required
13,24,25
. On the basis of limited evidence, 
chemical synovectomy appears effective but less so than radiosynovectomy
24
. For this reason, 
together with the need for immobilization and the degree of postprocedure pain, we do not use it 
in our practice.   
Several series exist of arthroscopic synovectomy in patients with hemophilia, although 
many are small series with short follow-up, or include synovectomy in joints other than the knee; 
these are excluded from this review
26
. De Almeida et al have published five year results of two-





primary outcome was the number of bleeding episodes in the operated joint each year in the five 
years following surgery, compared to the year before synovectomy; clinical scores (IKDC, 
WOMAC and SF-36), range of movement and radiological outcomes were collected as 
secondary outcome measures. Mean number of bleeding episodes reduced significantly from 20 
(SD 8.3) in the first year to between 0.8 (SD 2) and 3.7 (2.9) over subsequent years (p<0.05 at all 
time points). Significant improvements were reported in clinical scores (for instance, the median 
WOMAC score improved from 42 to 11, p=0.011); however, there was radiographic progression 
of disease over the five year follow-up period.  
Yoon et al report similar results after six-portal arthroscopic synovectomy (anterolateral, 
anteromedial, superolateral, superomedial, posteromedial and transeptal portals were used)
27
. 
Clinical and radiological results from a total of 28 knees in 26 patients with a mean age of 18 
years, all but one of whom had hemophilia A, were reported at a mean of six years. Hospital for 
Special Surgery (HSS) knee score improved from a mean of 56.4 points to a mean of 71.5 
(range: 41-89) at latest follow-up with little change in range of movement. Little radiographic 
change was noted, with radiographs being stable in 25 cases, and deteriorating in three. Eickhoff  
et al. reported the results of 10 patients following arthroscopic synovectomy, reporting 
significant improvement in eight with no improvement in two, with improvement in flexion 
deformity in six of the ten cases
28. Wiedel’s series of nine knees in eight patients followed-up for 
10-15 years reported a marked decrease in the incidence of bleeding even at long follow-up 
intervals, although again, radiographic progression of disease was noted
29
. In hemophilia, 
arthroscopic synovectomy is considered a major surgical procedure due to the risk of bleeding. 
Rampal et al reported their experience of open synovectomy, through a medial 
parapatellar approach, in 23 knees with a median follow-up of 8.8 years and a minimum follow-
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up of five years
30
. They again report improvements in clinical scores, along with range of 
movement, but progressive deterioration of radiological parameters. Teigland reported on nine 
open synovectomies at a mean follow-up of 12 years
31
. A radical approach was used with 
complete medial and lateral meniscectomies; while there were no recurrent bleeds, there was 
radiographic progression of degenerative change in all but one of the cases and six of the nine 
had resulted in either ankylosis or arthroplasty. Rodriguez-Merchan et al report on 27 
synovectomies in 27 patients, of which 18 were open and 9 were arthroscopic
32
. Groups were not 
matched and the arthroscopic and open groups were followed-up for different time periods (15 
years in the open group and 5 in the arthroscopic group. In both groups, the rate of post-operative 
bleeding was low (four of the 27 patients reported any bleeding) and none reported any pain or 
functional impairment as a result of postoperative hemarthrosis.  However, there was 
radiographic progression in both groups: in the open group; using the 13 point scale of Petterson 
and Gilbert
33
, there was a median deterioration of five points in the open group and one point in 
the arthroscopic group, reflecting the shorter follow-up of the latter. 
There are few studies directly comparing surgical synovectomy with radiosynovectomy, 
and the choice of first-line therapy differs by unit and treating physician. An expert review, 
based on 354 cases over 38 years being treated with radiosynovectomy (295 knees) or 
arthroscopic synovectomy (66 knees; some received both treatments) suggests that, if medical 
management has failed, radiosynovectomy should be preferred as a first-line treatment, but that 
arthroscopic synovectomy should be used in recalcitrant cases
34
. The only other comparative 
study is that of Triantafyllou et al comparing open with arthroscopic synovectomy in 13 cases, 
finding that both procedures reduced the incidence of hemarthrosis. Comparing the two 
procedures, open synovectomy was found to be more likely to result in a decreased range of 
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movement when compared to the arthroscopic procedure, and patients left hospital more quickly 
and required less coagulation factor infusion with the arthroscopic technique.  
In the authors’ experience, it is recommended to perform a radiosynovectomy before any type of 
surgical synovectomy, given that the nonsurgical method is much simpler and easier, and has 
similar results. Although radiosynovectomy can be performed at any age, for practical reasons 
we use radiosynovectomy with yttrium-90 in children over 12 years of age, and we prefer 
arthroscopic synovectomy in children under that age (in this age group, both methods would 
require anesthesia, removing one of the principal advantages of radiosynovectomy). The dose we 
use for knee radiosynovectomy is 185 megabequerels (MBq). Yttrium-90 is a pure beta-emitter, 
with therapeutic penetration power of 2.8 mm and an average half-life of 2.8 days. We do not 
perform chemical synovectomy because of the need for repeated weekly painful injections. 
 
Management of flexion contractures 
As a result of repeated hemarthroses, the inflamed synovium of the knee becomes fibrotic 
leading to arthrofibrosis, shortening of the muscles surrounding the joint, and progressive and 
severe contractures
7
. Contractures are common (affecting up to 95% of individuals with 
hemophilia) and can be disabling, even if the joint surfaces themselves remain intact
35
. 
Contractions can either be acute (neoflexum - <30 days following an episode of hemarthrosis); 
semiacute (paleoflexum, >30 days, <1 year); or chronic (archiflexum, >1 year with established 
arthropathy)
36
. Limitation of the range of movement can occur at either end of the range, but 




Physical therapy is the mainstay of preventative treatment for joint contractures
37
. For 
minor contractures, physiotherapy may be an effective form of treatment, with techniques 
including manual traction, muscle strengthening, joint stability and gait training being helpful
38
. 
Serial casting is a well-established treatment to improve the state of flexion contractures. 
Fernandez-Palazzi et al reported a series of 58 patients, undergoing serial casting over four to six 
weeks
39
. They describe an improvement in flexion deformity from a mean of 42.5º to a mean of 




More severe deformities require soft tissue procedures such as release of hamstrings or 
posterior capsule to allow full extension
41
. Wallny et al in 1999 reported a series of 27 patients 
undergoing hamstrings release with or without capsulotomy, describing immediate 
improvements post-operatively and reporting no complications (with most patients 
demonstrating full resolution of the contracture). However, long-term results (at a mean follow-
up of 12.5 years) demonstrated that only eleven patients maintained their range of movement 
with a mean loss of 10º. Five patients deteriorated to the extent that they were worse than at the 
latest follow-up than they were before the operation
42
. The authors recommend the technique in 
patients with severe deformities but essentially normal joint surfaces; total knee arthroplasty 
(TKA) is recommended in cases with joint degeneration. An alternative to surgical release is 
injection of botulinum toxin into affected muscles. Daffunchio et al report their experience of the 
use of botulinum toxin in 21 patients with at least a flexion contracture of 10º, refractory to 
physiotherapy
36
. Both paleoflexum and archiflexum cases were included, and contractures 
ranged from 10º to >46º. In mild to moderate contractures (those <45º), statistically significant 
improvements are described of between 44 and 46% (p=0.001 in mild contractures and p=0.007 
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in moderate contractures). In severe cases, there was a mean improvement of 30%, but this did 
not reach statistical significance. Botulinum toxin is commonly used in patients with muscle 
spasticity. Therefore, for us its role in muscle contractures like those seen in hemophiliacs is 
controversial. 
Soft tissue releases can be used in conjunction with an external fixator for progressive 
extension
43
 to address severe deformities. In the severest deformities, distal femoral osteotomies 
have been used to correct sagittal plane deformities, although the published data on such 
procedures in this patient population are limited. Caviglia et al describe the use of extension 
supracondylar osteotomies to correct flexion deformities in 19 patients
44
. Whilst the procedure 
does not increase the absolute range of movement, it improves function by returning the range 
that does exist into a more functionally useful position. It should be borne in mind that 
introducing a deformity to the distal femur will render future TKA more challenging. In most 
cases, these patients have severe joint degeneration and it is likely that these patients are more 
suitably treated with TKA.  
 
Total knee arthroplasty in hemophilia 
Patients with hemophilia who deteriorate to the extent of requiring TKA pose particular 
challenges to the arthroplasty surgeon, anesthetist and other clinical teams. Such patients should 
be managed by a multidisciplinary team in a center with experience of managing the 
perioperative care of patients with hemophilia
45
. Generally, any major surgery in patients without 
inhibitors is performed under hemostatic cover with bolus or continuous infusion of the relevant 
factor concentrate to prevent major perioperative bleeding
45
. Patients with inhibitors are more 
likely to bleed and have a higher rate of potential complications such as infection; until relatively 
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recently, major orthopedic procedures were only rarely performed in this group due to the 
potential for major bleeding but new products and protocols have rendered such procedures safer 
in such patients
46
. Prior to surgery, patients with inhibitors should be treated with ITI  or other 
agents such as rituximab or plasmapheresis to reduce the antibody titer as low as possible to 
allow emergent treatment with coagulation factors in the event of intraoperative or postoperative 
bleeding
47
. Bypassing agents such as recombinant factor VII activated (rFVIIa) or activated 
prothrombin complex concentrates (aPCCs) are given as repeated boluses intra- and 
postoperatively to prevent bleeding complications. In common with TKA performed for other 
reasons, the use of a multimodal bleeding prevention approach including intra-articular or oral 
tranexaminc acid has been introduced to cases performed for hemophilia
48
. 
In addition to hematological management, the principal challenges of TKA in 
hemophiliac patients are technical challenges (in particular, dealing with severe deformities and 
the need for constrained devices); prevention of venous thromboembolism; and managing the 
risk of prosthetic joint infection (PJI)
49
. In existing series, many of these problems are 
exacerbated by high rates of uncontrolled HIV infection secondary to the use of pooled blood 
transfusions in the 1980s. As the effect of this diminishes over time, we will have a truer idea of 
the rate of success of TKA in this population. However, several series exist which report 
excellent results in the medium to long term following TKA in such patients. 
 
Rate of complications following TKA in hemophilia 
A very  important study of the rate of complications after TKA in hemophilia is the 
database study of Cancienne et al
50
. These investigators  compared the outcomes of 3,396 
patients with hemophilia to a matched cohort of 427,132 patients without bleeding disorders, 
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reporting a small but statistically significantly higher rate of perioperative infection at three and 
six months (with odds ratios of 1.5 (2.0% v 1.3%, 95% CI 1.2-2.0) and 1.6 (3.5% v 2.2%, 95% 
CI 1.4-2.0) respectively) in the hemophilia cohort. Patients with hemophilia had a significantly 
higher risk of venous thromboembolism (VTE, OR 2.2, 95% CI 1.8-2.7), medical complications 
(OR 1.3, 95% CI 1.2-.15) and blood transfusion (OR 1.3, 95% CI 1.2-1.4). Revision was more 
likely in patients with hemophilia at all time points from six months to eight years (with odds 
ratios of between 1.4 and 1.5 at each time point). Hemophilia patients were no more likely to 
report stiffness than controls. In other published series, the rate of infection in hemophilia is 
consistently higher than that expected from TKA in OA; however, the situation appears to be 
improving, with later series reporting lower levels of infection (Table 2). It is not clear whether 
this is due to a lower proportion of patients with HIV, or whether it is solely due to an increased 
awareness of the risk of infection and improvements in prophylaxis. A separate meta-analysis of 
336 TKAs report a rate of infection of 7.1% and hemarthrosis in 7.7%
51
. 
Venous thromboembolism (VTE) is of particular interest in patients with hemophilia as 
the bleeding disorder itself may represent a contra-indication to thromboprophylaxis
52
. Several 
smaller studies have failed to determine a higher risk of deep vein thrombosis (DVT) or 
pulmonary embolism (PE) in hemophilia patients undergoing TKA, although the 
thromboprophylaxis regime varies. Buckner et al reported results from a multicenter 
observational study of 46 patients with a variety of thromboproxhylaxis regimens (calf 
compression in 23/46 patients, with a further four patients having chemical thromboprophylaxis 
with low molecular weight heparin)
53
. The investigators reported one symptomatic lower leg 
DVT (in a patient who had received calf compression), and one symptomatic PE (in a patient 
who had used compression stockings). No asymptomatic DVTs were diagnosed on ultrasound 
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examination of the remaining patients. A total of 18/46 patients had major bleeding during the 
study (defined as any intracranial or intraarticular bleed, or resulting in a drop in hemoglobin of 
≥2g/dL or requiring two units of blood), including two of the four patients who received heparin 
prophylaxis. A study of 38 patients undergoing ultrasound examination following TKA reported 
no patients with subclinical VTE
54
, whilst a study of 71 cases of hip and knee arthroplasty 
reported one case of symptomatic VTE on a patient who was receiving thromboprophylaxis
55
. 
This third study, of Perez Bortero et al, includes a review of the existing literature, encompassing 
1,107 joint replacements in 843 patients. Not including two asymptomatic VTEs detected on 
screening ultrasound, they report symptomatic VTE in six cases, giving an incidence of 0.5% 
(95% CI 0.1-0.9%)
55
. Overall, the evidence on VTE is inconsistent, and further studies are 
necessary to define the optimal form of VTE prophylaxis in this group of patients. 
 
Implant survival and functional outcome 
Table 2 gives details of all studies of TKA in hemophilia comprising at least ten patients 
and performed since 2000; a total of 1,029 TKAs are reported. In the eight studies reporting 
revision rates at ten years, implant survival ranges from 81% to 89%, which is substantially 
lower than that expected for TKA overall (the National Joint Registry for England, Wales and 
Northern Ireland reports a rate of survival of 96.6% (95% CI 96.5-96.7) for cemented TKA, 
irrespective of diagnosis
56
). However, the cohort of patients with hemophilia undergoing TKA 
are younger (with a mean age of 40 years in the studies referenced) and the vast majority are 
male. The ten year survival figure given in the same National Joint Registry report for males 
under the age of 55 is 91.8% (90% CI 89.4-91.3), with which the figures for hemophilia compare 
rather more favorably. Survival in later studies appears to be no better than in previous studies; 
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however, the higher mortality rate in earlier studies due to HIV infection may give a falsely high 
figure for implant survival.  
In studies reporting functional outcomes, substantial improvements in range of 
movement, Knee Society Score (objective and functional subsections, KSS-O and KSS-F) and 
Hospital for Special Surgery (HSS) score are reported in all studies. A meta-analysis of 336 
TKAs undertaken in patients with hemophilia supports these findings, with significant 





The widespread availability of coagulation factor concentrates has improved the long-
term function of the knee in patients with hemophilia in the developed world. However, in many 
countries and communities, severe musculoskeletal complications of hemophilia remain a 
substantial problem for orthopedic surgeons; even in developed countries, we continue to treat 
patients with the long-term consequences of years of hemophilic arthropathy.  
There is now an evidence basis for the treatment of the consequences of hemophilia in 
the knee. In the presence of synovitis, the use of radiosynovectomy appears to be safe with 
excellent results in terms of short term symptomatology, although no form of synovectomy has 
been demonstrated to improve long-term outcomes in terms of progression to symptomatic 
degenerative arthropathy of the knee. The use of conservative and operative measures to treat 
contractures can improve the quality of life of patients with hemophilia, whilst TKA can provide 
equivalent functional results in hemophilic arthropathy to those reported in degenerative or 
inflammatory arthritides. The results of TKA in hemophilia will be further improved by the 
18 
 
development of better perioperative care, in particular concerning prophylaxis for VTE and 
prosthetic joint infection. 
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Figure 1:  
Radiographs of a patient with bilateral end-stage arthrosis secondary to hemophilia. 
a – bilateral anteroposterior radiographs; b- bilateral lateral radiographs 
 
Figure 2:  
Fixed flexion contracture and synovitis in a patient with hemophilia 
